76,328 Shares in Aurinia Pharmaceuticals Inc $AUPH Bought by EntryPoint Capital LLC

Key Points

• EntryPoint Capital LLC acquired 76,328 shares of Aurinia Pharmaceuticals, valued at approximately $614,000, increasing its ownership to 0.06% of the company.
• Analysts have recently set a consensus target price of $12.00 for Aurinia Pharmaceuticals, with ratings ranging from "outperform" to "buy" from various brokerages.
• Insider transactions show Director Kevin Tang purchased 1,000,000 shares at $10.12 per share, increasing his position in the company significantly.

EntryPoint Capital LLC bought a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 76,328 shares of the biotechnology company's stock, valued at approximately $614,000. EntryPoint Capital LLC owned about 0.06% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $27,000. Tower Research Capital LLC TRC boosted its holdings in Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in Aurinia Pharmaceuticals in the 4th quarter valued at about $31,000. GAMMA Investing LLC boosted its holdings in Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 1,744 shares during the last quarter. Finally, Natixis acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Stock Down 1.6%

Shares of NASDAQ AUPH opened at $12.03 on Wednesday. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a 52 week low of $6.32 and a 52 week high of $12.53. The firm has a 50-day moving average price of $9.24 and a 200 day moving average price of $8.45. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 27.98 and a beta of 1.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The company had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on AUPH. Royal Bank Of Canada upped their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research note on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $12.00.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 1,000,000 shares of the business's stock in a transaction on Friday, August 1st. The stock was bought at an average price of $10.12 per share, for a total transaction of $10,120,000.00. Following the completion of the transaction, the director owned 11,029,500 shares in the company, valued at approximately $111,618,540. The trade was a 9.97% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 1,300,000 shares of company stock worth $13,590,000 in the last ninety days. Insiders own 12.20% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.